Primary navigation

    CGRP Antagonists

    Drug - Emgality™ 120 mg/mL prefilled pen and prefilled syringe (galcanezumab-gnlm) [Eli Lilly and Company]
               Aimovig™ (erenumab-aooe) [Amgen Inc.] 
               Ajovy™ (fremanezumab-vfrm) [Teva Pharmaceuticals USA, Inc.]
               Emgality™ 100 mg/mL prefilled syringe (galcanezumab-gnlm) [Eli Lilly and Company

    October 2020

    Therapeutic area - Antimigraine Preparations, CGRP Antagonists

    Initial approval criteria for Ajovy prefilled autoinjector, Ajovy prefilled syringe, Emgality 120mg/mL prefilled pen, Emgality 120mg/mL prefilled syringe (Preferred)

    • Preferred drug is prescribed by, or in consultation with a specialist (including neurologist or pain specialist) AND
    • Patient has a diagnosis of migraine with or without aura based on International Classification of Headache Disorders (ICHD-III) diagnostic criteria AND
    • Medication overuse headache has been ruled out by trial and failure of titrating off acute migraine treatments in the past AND
    • Patient has ≥ 4 migraine days per month for at least 3 months AND
    • Patient has tried and failed a ≥ 1 month trial of any 2 of the following oral medications:  
      • Antidepressants (e.g., amitriptyline, venlafaxine)
      • Beta blockers (e.g., propranolol, metoprolol, timolol, atenolol)
      • Anti-epileptics (e.g., valproate, topiramate)
      • Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan)
    • Initial approval is for 3 months

    Initial approval criteria for Aimovig (Nonpreferred)

    • Patient must meet all initial approval criteria for preferred drug AND
    • Patient has tried and failed a 3-month trial of the preferred drug, unless contraindicated
    • Initial approval is for 3 months

    Initial approval criteria for Emgality 100mg/mL prefilled syringe

    • Patient must be at least 18 years of age; AND
    • Emgality 100mg/mL prefilled syringe is prescribed by, or in consultation with a specialist (including neurologist or pain specialist); AND 
    • Patient has a diagnosis of episodic cluster headaches based on International Classification of Headache Disorders (ICHD-III) diagnostic criteria as documented in patient chart notes; AND
    • Patient has at least 5 attacks occurring in bouts (cluster periods) that meet the following criteria:
      • Severe or very severe unilateral orbital, supraorbital, and/or temporal pain lasting 15 to 180 minutes when untreated; during part (but less than half) of the active time course of cluster headache, attacks may be less severe and/or of shorter or longer duration AND
      • Either or both of the following:
        • At least one of the following symptoms or signs ipsilateral to the headache
          • Conjunctival injection and/or lacrimation OR
          • Nasal congestion and/or rhinorrhea OR
          • Eyelid edema OR
          • Forehead and facial swelling OR
          • Miosis and/or ptosis OR
        • A sense of restlessness or agitation AND
      • Attacks have a frequency between 1 every other day to 8 every day; during part (but less than half) of the active time-course of cluster headache, attacks may be less frequent; AND
    • Patient has experienced at least two cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least 3 months; AND
    • Medication overuse has been ruled out by trial and failure of titrating off treatments in the past AND
    • Patient has tried and failed a ≥ 1 month trial of the following oral medications:
      • Verapamil (maximum total daily dose of 480mg to 960mg, unless contraindicated or maximum daily dose cannot be reached due to intolerance) AND
      • Topiramate (maximum total daily dose of 100mg, unless contraindicated or maximum daily dose cannot be reached due to intolerance)
    • Initial approval is for 3 months

    Renewal criteria for all CGRP antagonists

    • Patient demonstrated significant decrease in the number, frequency, and/or intensity of headaches AND
    • Patient has an overall improvement in function with therapy AND
    • Has not reached the end of the cluster period, if for cluster headaches AND
    • Absence of unacceptable toxicity (e.g., intolerable injection site pain)
    • Renewal approval is for 12 months

    Quantity limits

    • Ajovy: 1 prefilled autoinjector or syringe per 30 days
    • Aimovig: 2 syringes or autoinjectors per 30 days
    • Emgality:
      • 120mg/mL prefilled syringe or prefilled pen: 2 prefilled pens or syringes for the first 30 days; 1 prefilled pen or syringe per 30 days thereafter
      • 100mg/mL prefilled syringe: 3 prefilled syringes every 30 days

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top